Pharmacovigilance and Risk Management Strategies 2014

Featured

Want to learn more about Pharmacovigilance and Risk Management Strategies 2014? You've come to the right site!

Continuing-Education

Learn more

Continuing-Education

Learn more

Short Course or Primer

To keep you at the forefront.

Jan 12, 2014

Tutorial #1 – Pharmacovigilance and Risk Management Planning:

Learn more

Jan 12, 2014

Tutorial #2 – Introduction to Pharmacoepidemiology and Applications in Premarketing and Postmarketing Surveillance, Risk Management, and Value Demonstration:

Learn more

Jan 12, 2014

Tutorial #3 – ICH E2C (R2):

The Quantum Leap from PSURs to Benefit-Risk Evaluation (PBRERs)

Learn more

Jan 12, 2014

Tutorial #4 – Pharmacovigilance System Master File:

Learn more

Jan 12, 2014

Tutorial #1 – Pharmacovigilance and Risk Management Planning:

Learn more

Jan 12, 2014

Tutorial #2 – Introduction to Pharmacoepidemiology and Applications in Premarketing and Postmarketing Surveillance, Risk Management, and Value Demonstration:

Learn more

Jan 12, 2014

Tutorial #3 – ICH E2C (R2):

The Quantum Leap from PSURs to Benefit-Risk Evaluation (PBRERs)

Learn more

Jan 12, 2014

Tutorial #4 – Pharmacovigilance System Master File:

Learn more

Program Committee

JP Clement, MD Founder and Principal
JPCC Associates, United States
William Gregory, PhD Senior Director, Safety and Risk Management
Pfizer Inc, United States
Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Worldwide Safety Officer
Bristol-Myers Squibb Company, United States
E. Stewart Geary, MD Senior Vice President
Eisai Co., Ltd., Japan
Stephen Knowles, MD, MRCP Chief Medical Officer
Halozyme Therapeutics, United States
Michael Richardson, MD, FFPM, FRCP Senior Vice President, WorldWide Patient Safety
Bristol-Myers Squibb, United Kingdom
Tracy Salaam, PharmD Regulatory Policy Analyst
FDA, United States